Your browser is no longer supported. Please, upgrade your browser.
Moleculin Biotech, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own2.08% Shs Outstand28.57M Perf Week-2.26%
Market Cap49.77M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float27.98M Perf Month-16.43%
Income-15.70M PEG- EPS next Q-0.21 Inst Own13.90% Short Float1.86% Perf Quarter-35.45%
Sales- P/S- EPS this Y9.40% Inst Trans- Short Ratio1.84 Perf Half Y-47.42%
Book/sh2.84 P/B0.61 EPS next Y-43.70% ROA-20.20% Target Price19.00 Perf Year-71.73%
Cash/sh2.61 P/C0.66 EPS next 5Y- ROE-23.10% 52W Range1.64 - 8.78 Perf YTD-6.99%
Dividend- P/FCF- EPS past 5Y-62.90% ROI- 52W High-80.30% Beta1.73
Dividend %- Quick Ratio21.10 Sales past 5Y- Gross Margin- 52W Low5.49% ATR0.11
Employees10 Current Ratio21.10 Sales Q/Q- Oper. Margin- RSI (14)38.02 Volatility4.12% 6.10%
OptionableNo Debt/Eq0.00 EPS Q/Q53.70% Profit Margin- Rel Volume0.33 Prev Close1.71
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume283.79K Price1.73
Recom1.70 SMA20-6.61% SMA50-16.93% SMA200-41.72% Volume94,642 Change1.17%
Jan-18-22 08:05AM  
Jan-12-22 10:35AM  
Jan-07-22 08:30AM  
Dec-27-21 08:05AM  
Dec-01-21 08:35AM  
Nov-12-21 08:05AM  
Nov-11-21 08:05AM  
Nov-04-21 02:30PM  
Oct-20-21 05:46PM  
Oct-19-21 09:05AM  
Oct-18-21 08:25AM  
Sep-27-21 07:05AM  
Sep-17-21 08:05AM  
Sep-08-21 08:00AM  
Aug-12-21 08:18AM  
Aug-03-21 06:29AM  
Jul-13-21 08:35AM  
Jun-22-21 08:30AM  
Jun-21-21 08:35AM  
Jun-15-21 09:05AM  
May-25-21 11:23AM  
May-12-21 07:35AM  
May-11-21 08:05AM  
Apr-14-21 09:38AM  
Apr-06-21 07:30AM  
Mar-30-21 07:30AM  
Mar-24-21 07:30AM  
Mar-09-21 07:30AM  
Feb-10-21 04:15PM  
Feb-08-21 07:30AM  
Feb-05-21 07:30AM  
Feb-04-21 03:24AM  
Feb-03-21 08:30AM  
Feb-02-21 04:22PM  
Feb-01-21 07:30AM  
Jan-29-21 09:15AM  
Jan-12-21 10:40AM  
Jan-07-21 07:30AM  
Dec-29-20 07:30AM  
Dec-17-20 07:30AM  
Dec-03-20 07:30AM  
Dec-01-20 07:30AM  
Nov-19-20 07:30AM  
Nov-13-20 07:30AM  
Oct-29-20 07:30AM  
Oct-27-20 07:30AM  
Oct-21-20 07:30AM  
Oct-13-20 07:30AM  
Oct-06-20 07:30AM  
Oct-05-20 07:30AM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-14-20 07:30AM  
Sep-10-20 07:30AM  
Sep-09-20 01:52PM  
Aug-27-20 07:30AM  
Aug-12-20 07:30AM  
Aug-11-20 09:13AM  
Jul-21-20 09:59AM  
Jul-16-20 11:11AM  
Jul-15-20 07:30AM  
Jul-03-20 11:30AM  
Jul-02-20 07:30AM  
Jul-01-20 05:50PM  
Jun-30-20 09:00AM  
Jun-29-20 08:35AM  
Jun-25-20 07:30AM  
Jun-23-20 08:49AM  
Jun-17-20 11:30AM  
Jun-16-20 07:30AM  
Jun-04-20 07:30AM  
Jun-02-20 07:30AM  
Jun-01-20 11:30AM  
May-27-20 05:55PM  
May-18-20 02:47PM  
May-13-20 11:30AM  
May-11-20 08:36AM  
May-08-20 05:09PM  
May-06-20 08:39AM  
May-05-20 05:45PM  
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.